<?xml version="1.0" encoding="UTF-8"?>
<p>CEPI is prioritizing investments in two areas. The first is the development of vaccines against a set of high-priority pathogens, which currently include Lassa, MERS-CoV, Nipah, RVF, and Chikungunya viruses. The second is the development of vaccine platform technologies that will enable rapid vaccine development and manufacturing to improve global capacity to respond to the emergence of an unknown pathogen with epidemic potential (Disease X) [
 <xref ref-type="bibr" rid="CR26">26</xref>].
</p>
